Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. It focuses on the development of drug class based on the central action mechanism of Aminopeptidase A inhibition. The company was founded by Lionel Ségard on December 23, 2005 and is headquartered in Paris, France.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company